Related Experiment Videos
Therapy of human papillomavirus infection and associated epithelial tumors
1Department of Dermatology, University of Rostock, Germany.
Abstract:
Papillomavirus infections are very common and cause various benign and malignant lesions, most notably condyloma acuminatum, anogenital cancer, laryngeal papilloma and skin warts. Unfortunately, effective therapy is currently not available. Therapeutic options are limited, expensive and often ineffective. They comprise cytodestructive and cytotoxic substances, surgical methods, laser and cryotherapy. Immunotherapy seems to be one of the more promising options. Interferons combined with ablative methods such as CO2 laser can prevent recurrence of disease. Cytokine enhancement is an old concept that has shown effectiveness with imidazoquinolinamine derivatives (imiquimod). Imiquimod was released recently for therapy of genital warts. Currently, HPV vaccines are being developed to protect against infection with HPV and to treat existing warts and other HPV-associated lesions. Some processes in the HPV infection cycle have been determined as possible targets for the development of specific antiviral agents. Cidofovir is a primordial antiviral substance active against HPV. Unfortunately, there is a potential risk for side effects.
Insights
Papillomavirus infections cause various lesions, with limited effective therapies. Immunotherapy and new antiviral agents show promise for treating human papillomavirus (HPV) infections and associated conditions.
Area of Science:
- Virology
- Dermatology
- Oncology
Background:
- Human papillomavirus (HPV) infections are prevalent, causing benign and malignant lesions like warts and cancers.
- Current therapeutic options for HPV-related conditions are often limited, costly, and ineffective.
- Existing treatments include destructive substances, surgery, laser, and cryotherapy.
Purpose of the Study:
- To review current and emerging therapeutic strategies for human papillomavirus (HPV) infections.
- To highlight the potential of immunotherapy and novel antiviral agents in managing HPV-associated lesions.
Main Methods:
- Literature review of existing and investigational therapies for HPV infections.
- Analysis of treatment modalities including conventional methods, immunotherapy, and antiviral agents.
- Discussion of emerging therapeutic targets within the HPV infection cycle.
Main Results:
- Immunotherapy, such as interferons combined with ablative methods, may prevent disease recurrence.
- Cytokine enhancement with imiquimod has demonstrated effectiveness, with recent approval for genital warts.
- Novel approaches include HPV vaccines and specific antiviral agents like cidofovir, though potential side effects exist.
Conclusions:
- Effective therapy for human papillomavirus (HPV) infections remains a challenge.
- Immunotherapy and emerging antiviral agents represent promising avenues for managing HPV-related diseases.
- Further research into HPV-specific targets and treatments is crucial for improved patient outcomes.